日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. CFP (NM-3086 Biosimilar) Recombinant Monoclonal Antibody

CFP (NM-3086 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA005291MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CFP (NM-3086 Biosimilar Antibody)重組抗體是一種用于科研領域的重組單克隆抗體產(chǎn)品。該抗體通過重組DNA技術制備，具有高度的特異性和均一性，為生命科學研究提供了可靠的工具。 作為科研用試劑，該產(chǎn)品可廣泛應用于多種實驗場景，包括但不限于蛋白質(zhì)印跡、以及酶聯(lián)免疫吸附測定（ELISA）等。其高度純化的特性確保了實驗結(jié)果的準確性和可重復性，有助于科研人員在基礎研究、藥物靶點發(fā)現(xiàn)、疾病機制探討等方面獲得可靠的數(shù)據(jù)支持。 該重組單克隆抗體的研發(fā)嚴格遵循高標準的生產(chǎn)工藝，在生產(chǎn)過程中采用了先進的質(zhì)量控制體系，確保每一批次產(chǎn)品的穩(wěn)定性和一致性。其明確的靶向性能夠特異性識別目標抗原，為研究人員提供了精確的實驗手段，助力揭示生物分子間的相互作用及調(diào)控機制。 在科研應用中，該抗體產(chǎn)品能夠滿足不同實驗體系的需求，為生命科學領域的創(chuàng)新研究提供有力支持。無論是細胞生物學研究、分子機制探索，還是疾病模型構建等方面，都能發(fā)揮重要作用，推動相關領域的科學發(fā)現(xiàn)和技術進步。
  • Uniprot No.：
  • 基因名：
  • 別名：
    NM3086 research-grade biosimilar; NM 3086 research-grade biosimilar; NM-3086 research-grade biosimilar; Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody research-grade biosimilar ;CFP antibody; PFC antibody; Properdin antibody; Complement factor P antibody
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human CFP protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    A positive regulator of the alternate pathway (AP) of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes. Inhibits CFI-CFH mediated degradation of Complement C3 beta chain (C3b).
  • 基因功能參考文獻：
    1. In conclusion, we challenge the view of properdin as a pattern recognition molecule by providing evidence that it binds to different exogenous and endogenous molecular patterns in only a C3-dependent manner. PMID: 28069958
    2. data indicate that properdin enhances platelet/granulocyte aggregates (PGAs) formation via increased production of C5a, and that inhibition of properdin function has therapeutic potential to limit thromboinflammation in diseases characterized by increased PGA formation PMID: 27183616
    3. this study shows that RNA interference of properdin in dendritic cells decreased alloantigen-specific T-cell proliferation PMID: 28105653
    4. studies demonstrate an essential role of properdin oligomerization in vivo while our monomers enable detailed structural insight paving the way for novel modulators of complement. PMID: 28264884
    5. P serum level expression could be a reliable clinical biomarker to identify patients with underlying surface alternative pathway C5 convertase dysregulation. PMID: 26660535
    6. can directly interact with neutrophil myeloperoxidase resulting in activation of alternative pathway of complement PMID: 24355864
    7. In the pathogenesis of renal tubular damage, P can directly bind to PTECs and may accelerate AP activation by surpassing fH regulation PMID: 24885016
    8. Our data show that physiological forms of human properdin bind directly to human platelets after activation by strong agonists in the absence of C3 PMID: 23677468
    9. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. PMID: 22815489
    10. Properdin released from human polymorphonuclear cells does not bind to zymosan or E. coli, but when incubated in properdin-depleted serum this form of properdin binds efficiently to both substrates in a strictly complement C3-dependent manner. PMID: 22851705
    11. Properdin and SC5b-9 may be novel biomarkers for future risk of type 2 diabetes in this high-risk population and warrant further investigation. PMID: 22338105
    12. Immune human serum that contained bactericidal Abs directed against the 2C7 lipooligosaccharide epitope required functional properdin to kill C4BP-binding strains, but not C4BP-nonbinding strains. PMID: 22368277
    13. report a large Finnish family with a novel mutation in the properdin gene. The mutation is located in exon 9 and changes guanine to adenine at nucleotide 1164 (c.1164G>A) that causes tryptophan to change to a premature stop codon (W388X). PMID: 22229731
    14. tubular HS as a novel docking platform for alternative pathway activation via properdin, which might play a role in proteinuric renal damage. PMID: 21135110
    15. levels of properdin are not associated with childhood wheezing and atopy PMID: 20337960
    16. Human properdin can selectively recognize surfaces and enhance or promote alternative pathway of complement activation. PMID: 20382442
    17. The conventional mechanism of properdin function is to bind to and stabilize alternative pathway C3 convertases on the surface of Neisseria meningitidis and N. gonorrhoeae. PMID: 20530262
    18. Properdin presence is associated with increased SC5b-9 excretion and worse renal function. PMID: 19934084
    19. CFP does not seem to confer any risk for age-related macular degeneration. PMID: 20122735
    20. A splice site mutation in exon 10 (c.1487-2A>G) was found in the properdin gene and co segregated with biochemically measured properdin deficiency. PMID: 16337490
    21. study reports properdin binds predominantly to late apoptotic & necrotic cells but not to early apoptotic cells; binding occurs independently of C3b PMID: 18490764
    22. The human complement protein properdin binds to early apoptotic T cells and initiates complement activation, leading to C3b opsonization and ingestion by phagocytic cells. PMID: 18579773
    23. The contribution of properdin is pivotal in proteinuria-induced tubular complement activation and subsequent damage. Interference with properdin binding to tubular cells may provide an option for the treatment of proteinuric renal disease. PMID: 18753294
    24. Properdin induces the formation of platelet-leukocyte aggregates via leukocyte activation, linking the complement system & platelet-leukocyte aggregates with potential significance in atherosclerotic vascular disease. PMID: 18791942
    25. Significantly more transcripts encoding alternative pathway components factor B, C3 and properdin, and C3a receptor and C5a receptor were detected in grade 3 versus grade 0 or 1 biopsies of human cardiac allografts. PMID: 19005416
    26. Factor P was expressed in 50% of choroidal neovascular membranes of patients with age-related macular degeneration(AMD). Additional studies need to investigate role of Factor P in development of AMD for potential therapeutic intervention. PMID: 19584655

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Properdin deficiency (PFD)
  • 亞細胞定位：
    Secreted.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 8864

    OMIM: 300383

    KEGG: hsa:5199

    STRING: 9606.ENSP00000247153

    UniGene: Hs.53155



×
生命科學計算平臺